Pain Post Abdominal Laparoscopy Prevention With Arcoxia

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00565682

Enrollment

Registered

2007-11-30

Start date

2006-04-30

Completion date

2006-12-31

Last updated

2007-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Surgery for Appendicitis, Laparoscopic Surgery for Cholecystitis, Laparoscopic Surgery for Ovarian Cysts

Brief summary

To test the analgesic efficacy of etoricoxib used before a surgical procedure compared to the already known effect when administered after such a procedure. Patient will be receiving either etoricoxib or the respective placebo one hour before surgery, then two hours after those receiving the active will receive placebo and those that received placebo will be given etoricoxib. Pain score measurements will be performed sequentially. Rescue medication will be available all the time.

Interventions

DRUGetoricoxib 120 mg

etoricoxib 120 mg, tablet, orally, OD

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Voluntary acceptance to participate in the study and signed the informed consent form * Age older than 18 years old and younger than 70 years * Diagnosis of appendicitis, cholecystitis or ovarian cysts suitable of laparoscopic surgery

Exclusion criteria

* Age less than 18 years or older than 70 years. * Laparoscopic procedures for diagnostic purposes. * Current use of anticoagulants. * Known hypersensitivity to etoricoxib or its components. * History of a CABG or MI (less than 1 year) * History of unstable angina (over the past six months). * Current inflammatory bowel disease. * Uncontrolled hypertension or heart failure * Renal dysfunction/impairment (creatinine clearance \< 30ml/min) * Cirrhosis or severe hepatic dysfunction * Any degree of dehydration (mild to severe)

Design outcomes

Primary

Measure	Time frame
To measure the amount of rescue medication (opioid) needed to relief	Every hour after surgery

Secondary

Measure	Time frame
To determine the overall analgesic effect using the visual analog scale (VAS)	Every hour after surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026